<DOC>
	<DOCNO>NCT00463814</DOCNO>
	<brief_summary>The primary purpose study assess safety , tolerability pharmacokinetics capsule AZD6244 patient advance solid malignancy .</brief_summary>
	<brief_title>AZD6244 ( ARRY-142886 ) Solid Oral Dosage Formulation Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>cancer refractory standard therapy WHO performance status 02 evidence postmenopausal status negative pregnancy test Radiotherapy/chemotherapy within 21 day prior entry brain metastases/spinal cord compression unless stable steroids/anticonvulsants evidence severe/uncontrolled systemic disease participate investigational drug study within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Advanced Malignancy</keyword>
	<keyword>Cancer Eligibility</keyword>
	<keyword>Malignancy</keyword>
</DOC>